Increased 5-HT2C receptor editing predisposes to PTSD-like behaviors and alters BDNF and cytokines signaling.
Amygdala
/ metabolism
Animals
Anxiety
/ genetics
Behavior, Animal
/ drug effects
Brain-Derived Neurotrophic Factor
/ genetics
Cytokines
/ metabolism
Disease Models, Animal
Fear
Hippocampus
/ metabolism
Male
Maze Learning
Mice
Mice, Inbred C57BL
Mice, Transgenic
Paroxetine
/ pharmacology
RNA Editing
RNA, Messenger
/ genetics
Receptor, Serotonin, 5-HT2C
/ genetics
Signal Transduction
Stress Disorders, Post-Traumatic
/ drug therapy
Journal
Translational psychiatry
ISSN: 2158-3188
Titre abrégé: Transl Psychiatry
Pays: United States
ID NLM: 101562664
Informations de publication
Date de publication:
21 02 2019
21 02 2019
Historique:
received:
25
07
2018
accepted:
27
01
2019
revised:
24
01
2019
entrez:
23
2
2019
pubmed:
23
2
2019
medline:
16
1
2020
Statut:
epublish
Résumé
Post-traumatic stress disorder (PTSD) is a trauma- and stress-related disorder with dysregulated fear responses and neurobiological impairments, notably at neurotrophic and inflammation levels. Understanding the mechanisms underlying this disease is crucial to develop PTSD models that meet behavioral and neurobiological validity criteria as well as innovative therapeutic approaches. Serotonin 2C receptors (5-HT2CR) are known for their important role in anxiety, and mice having only the fully edited VGV isoform of 5-HT2CR, which thereby overexpressed brain 5-HT2CR, are of special interest to study PTSD predisposition. Innate and conditioned fear-related behaviors were assessed in VGV and wild-type mice. mRNA expression of brain-derived neurotrophic factor (BDNF), tissue-plasminogen activator (tPA), and pro-inflammatory cytokines (IL-6, IL-1β, and calcineurin) were measured by qRT-PCR. The effect of acute and chronic paroxetine was evaluated on both behavior and gene expression. VGV mice displayed greater fear expression, extensive fear extinction deficits, and fear generalization. Paroxetine restored fear extinction in VGV mice when administered acutely and decreased innate fear and fear generalization when administered chronically. In parallel, Bdnf, tPA, and pro-inflammatory cytokines mRNA levels were dysregulated in VGV mice. Bdnf and tPA mRNA expression was decreased in the hippocampus but increased in the amygdala, and chronic paroxetine normalized Bdnf mRNA levels both in the amygdala and the hippocampus. Amygdalar calcineurin mRNA level in VGV mice was also normalized by chronic paroxetine. VGV-transgenic mice displayed behavioral and neurobiological features that could be accessory to the investigation of PTSD and its treatment. Furthermore, these data point out to the role of 5-HT2CR in neuroplasticity and neuroinflammation.
Identifiants
pubmed: 30792491
doi: 10.1038/s41398-019-0431-8
pii: 10.1038/s41398-019-0431-8
pmc: PMC6384909
doi:
Substances chimiques
5-hydroxytryptamine2C receptor, mouse
0
Bdnf protein, mouse
0
Brain-Derived Neurotrophic Factor
0
Cytokines
0
RNA, Messenger
0
Receptor, Serotonin, 5-HT2C
0
Paroxetine
41VRH5220H
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
100Références
Biol Psychiatry. 2015 Sep 1;78(5):344-53
pubmed: 25727177
Mol Psychiatry. 2007 Jul;12(7):656-70
pubmed: 17264839
Science. 2006 Oct 6;314(5796):140-3
pubmed: 17023662
Science. 2010 Feb 12;327(5967):863-6
pubmed: 20075215
Nat Neurosci. 2006 Apr;9(4):519-25
pubmed: 16501568
Ann Clin Psychiatry. 2012 Aug;24(3):241-2
pubmed: 22860244
Br J Pharmacol. 2008 Sep;155(2):276-84
pubmed: 18552871
J Clin Psychiatry. 2008 Mar;69(3):400-5
pubmed: 18348595
J Neurosci. 2003 May 1;23(9):3855-68
pubmed: 12736356
Mol Pharmacol. 2007 Aug;72(2):350-8
pubmed: 17456785
Behav Brain Res. 2014 Dec 15;275:88-95
pubmed: 25193320
Biol Psychiatry. 2007 Nov 15;62(10):1111-8
pubmed: 17524369
Eur J Neurosci. 2000 Mar;12(3):1002-12
pubmed: 10762331
J Neurosci. 2013 Oct 9;33(41):16189-99
pubmed: 24107951
Learn Mem. 2004 Nov-Dec;11(6):770-86
pubmed: 15537742
Nature. 2016 Sep 1;537(7618):97-101
pubmed: 27556938
J Neurosci. 2014 Sep 10;34(37):12470-80
pubmed: 25209285
Ann Pharmacother. 2009 Jul;43(7):1220-6
pubmed: 19584388
Hippocampus. 2011 Apr;21(4):434-45
pubmed: 20087884
Mol Neurobiol. 2017 Aug;54(6):3964-3975
pubmed: 27289225
Genes Brain Behav. 2009 Jul;8(5):541-5
pubmed: 19496825
BMC Psychiatry. 2013 Jan 29;13:40
pubmed: 23360282
Brain Behav Immun. 2015 Feb;44:159-66
pubmed: 25451612
Front Immunol. 2016 Jun 06;7:219
pubmed: 27375619
Front Cell Neurosci. 2014 Dec 22;8:430
pubmed: 25565964
J Neurosci. 2004 May 19;24(20):4796-806
pubmed: 15152040
J Neurosci. 2007 Feb 7;27(6):1467-73
pubmed: 17287521
Neuropharmacology. 2010 Nov;59(6):468-73
pubmed: 20624407
Int J Neuropsychopharmacol. 2011 Jul;14(6):768-83
pubmed: 20946699
Prog Neuropsychopharmacol Biol Psychiatry. 2016 Feb 4;65:78-84
pubmed: 26344640
Biol Psychiatry. 2010 Feb 15;67(4):339-45
pubmed: 19914601
J Neurosci Res. 2005 Mar 15;79(6):756-71
pubmed: 15672416
Neuropharmacology. 2013 Jan;64:403-13
pubmed: 22722027
Genes Brain Behav. 2007 Jul;6(5):491-6
pubmed: 17451451
J Neurosci. 2003 Mar 1;23(5):1574-9
pubmed: 12629159
Neurobiol Aging. 2008 Sep;29(9):1380-93
pubmed: 17467122
Biol Psychiatry. 2004 Jul 15;56(2):121-8
pubmed: 15231444
Biol Mood Anxiety Disord. 2012 May 18;2:9
pubmed: 22738125
J Neurosci. 2009 Apr 1;29(13):4056-64
pubmed: 19339601
Prostaglandins Leukot Essent Fatty Acids. 2004 Sep;71(3):161-9
pubmed: 15253885
Neurosci Biobehav Rev. 2016 Jan;60:31-42
pubmed: 26519776
JAMA Psychiatry. 2014 Apr;71(4):423-31
pubmed: 24576974
Neuropsychopharmacology. 2015 Mar 13;40(5):1289-96
pubmed: 25430780
Psychopharmacology (Berl). 2013 Jul;228(1):97-107
pubmed: 23407783
Depress Anxiety. 2009;26(12):1110-7
pubmed: 19918929
Mol Psychiatry. 2012 Jan;17(1):22-35
pubmed: 21931317
J Neurochem. 2010 Oct;115(2):438-49
pubmed: 20796171
Behav Pharmacol. 2006 Feb;17(1):9-18
pubmed: 16377959
PLoS One. 2014 Dec 16;9(12):e114451
pubmed: 25514629
Int Clin Psychopharmacol. 1999 Mar;14(2):61-8
pubmed: 10220119
PLoS One. 2008 Sep 24;3(9):e3248
pubmed: 18813339
Biol Psychiatry. 2016 May 15;79(10):814-822
pubmed: 26248536
Pharmacol Biochem Behav. 2008 Mar;89(1):11-6
pubmed: 18067955
Mol Psychiatry. 2001 Sep;6(5):579-85
pubmed: 11526472
Neuroreport. 2010 Oct 27;21(15):993-7
pubmed: 20802353
Mol Psychiatry. 2013 Jun;18(6):656-65
pubmed: 23247076
Arch Gen Psychiatry. 1997 Aug;54(8):749-58
pubmed: 9283511
Clin Psychol Rev. 2012 Nov;32(7):630-41
pubmed: 22917742
Nat Rev Neurosci. 2012 Nov;13(11):769-87
pubmed: 23047775
J Neurosci. 2008 Oct 15;28(42):10576-86
pubmed: 18923034
Behav Res Ther. 2007 Sep;45(9):2019-33
pubmed: 17442266
Neuropsychopharmacology. 2014 Apr;39(5):1187-95
pubmed: 24247044
Prog Neuropsychopharmacol Biol Psychiatry. 2010 Oct 1;34(7):1279-84
pubmed: 20643177
Neurotox Res. 2016 Jan;29(1):47-53
pubmed: 26459304
Brain Res Mol Brain Res. 2004 Apr 29;124(1):70-8
pubmed: 15093687
Soc Psychiatry Psychiatr Epidemiol. 2015 Apr;50(4):525-37
pubmed: 25398198
Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8699-704
pubmed: 8710934
Biol Psychiatry. 2013 Jun 1;73(11):1078-86
pubmed: 23260230
Psychoneuroendocrinology. 2007 Sep-Nov;32(8-10):1106-15
pubmed: 17976923
CNS Neurosci Ther. 2011 Aug;17(4):227-36
pubmed: 20406268
Life Sci. 1999;65(17):1773-86
pubmed: 10576557
Neuropharmacology. 2009 Sep;57(3):259-67
pubmed: 19501602
Neuropharmacology. 2014 Jan;76 Pt C:677-83
pubmed: 23688925
Neuroreport. 2008 Feb 12;19(3):379-82
pubmed: 18303585
Pharmacol Ther. 2015 Mar;147:1-11
pubmed: 25444754
Psychopharmacology (Berl). 1997 Feb;129(3):197-205
pubmed: 9084057
Neuropsychopharmacology. 2008 Jan;33(1):73-83
pubmed: 17882234
Biol Psychol. 2014 May;99:150-9
pubmed: 24695006
World J Biol Psychiatry. 2018 Nov 1;:1-19
pubmed: 30230406
Cochrane Database Syst Rev. 2010 Jul 07;(7):CD007316
pubmed: 20614457
J Psychopharmacol. 2013 Oct;27(10):930-9
pubmed: 23863923
Psychopharmacology (Berl). 2005 Feb;177(4):448-58
pubmed: 15289999
Am J Med Genet B Neuropsychiatr Genet. 2009 Jul 5;150B(5):601-37
pubmed: 18802918
eNeuro. 2016 Nov 2;3(5):
pubmed: 27844053
Transl Psychiatry. 2015 Dec 15;5:e696
pubmed: 26670281
Int J Immunopathol Pharmacol. 2013 Apr-Jun;26(2):299-304
pubmed: 23755745
Acta Psychiatr Scand Suppl. 1989;350:24-6
pubmed: 2530779
Brain Res. 1992 Feb 14;572(1-2):117-25
pubmed: 1351783
Nat Neurosci. 2008 May;11(5):572-8
pubmed: 18425121
Neuroscience. 2002;113(4):995-1001
pubmed: 12182903
Ann N Y Acad Sci. 2006 Jul;1071:324-34
pubmed: 16891581
Neuropsychopharmacology. 2014 Aug;39(9):2161-9
pubmed: 24625752
Nat Neurosci. 2003 Feb;6(2):168-74
pubmed: 12524546
J Pharmacol Pharmacother. 2013 Oct;4(4):303-6
pubmed: 24250214
Int J Psychophysiol. 2015 Dec;98(3 Pt 2):594-605
pubmed: 25462219
Neuropsychopharmacology. 2001 May;24(5):478-91
pubmed: 11282248
Hum Mol Genet. 2014 Sep 15;23(18):4801-13
pubmed: 24781207
Neurosci Biobehav Rev. 2014 May;42:208-23
pubmed: 24631644
Exp Neurol. 2014 May;255:19-29
pubmed: 24582917
PLoS One. 2011;6(12):e28441
pubmed: 22174809
Int J Neuropsychopharmacol. 2014 Oct 31;18(3):
pubmed: 25522398